BiOrion Technologies, Immunitrack, Xenopat and Akademiska Sjukhuset Uppsala receive a EUROSTARS grant for their € 1.7 M colorectal cancer imaging program COLOSELECT
The EUROSTARS grant of a EUR 1.7 million colorectal cancer imaging program is awarded to a multidisciplinary consortium including BiOrion Technologies BV, The Netherlands, Immunitrack ApS. Denmark, Xenopat SL, Spain, and PET Centre, Akademiska Sjukhuset, Uppsala, Sweden.
EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 EUROSTARS Participating States and Partner Countries and by the European Union through Horizon 2020. The subsidy is for a three-year period and will allow clinical development of PDGF beta receptor binding single domain antibodies conjugated to PET-imaging and therapeutic radionuclides and to target fibrotic stroma in advanced colorectal sis.
Herman Steen, CEO of BiOrion, "We are delighted with the recognition and support for our PDGF beta receptor binding single domain antibodies targeting program by EUROSTARS. This strong and synergistic consortium will enable BiOrion to progress clinical development of our novel targeted imaging diagnostics and therapeutics against fibrotic stroma of solid cancers.”
Stephan Thorgrimsen, CEO of Immunitrack, “We are excited to be a part of COLOSELECT, and we believe that our unmatched experience within T cell epitope mapping and deimmunisation of biologics will make a major contribution to the project.”
Prof. Gunnar Antoni Head of PET Centre Akademiska Sjukhuset, “This grant and collaboration give us resources for development of new and specific diagnostic imaging using PET for colorectal cancer”.
Anna Portela, CEO of Xenopat, “We are proud to be a part of COLOSELECT. Xenopat will cooperate in the consortium by bringing the expertise needed to generate new CRC CSM4 PDX models, that will be of great use in the pre-clinical development of the newly designed antibodies.”
About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include hepatic, pulmonary and kidney fibrosis, among many others, and fibrosis-associated cancers such as colorectal cancer. BiOrion's platform and drug development engine is based on proprietary PDGF-ß-receptor binding peptides and single domain antibodies that act as targeting vehicles for diagnostic PET radionuclides, therapeutic radionuclides and (existing) anti-fibrotic therapeutics.
Herman Steen, PhD, CEO BiOrion Technologies BV
Immunitrack is a world leader in CD4 and CD8 T cell epitope mapping and protein expression. Its target market consists of companies developing new biotherapeutics, vaccines, cancer immunotherapy and patient immune monitoring. Within the scope of this project Immunitrack will apply its NeoScreen® platform for immunogenicity assessments and potential deimmunisation of the single-domain antibody. It will also expand its capabilities to include VHH nanobody expression and production.
Stephan Thorgrimsen, PhD, CEO
Xenopat is a privately-owned spin-off company of the Catalan Institute of Oncology, the Bellvitge Biomedical Research Institute and Bellvitge University Hospital. Through use of its orthoxenografts® models, it provides services focusing on personalized cancer treatment assessment and advanced preclinical services. Orthoxenografts® are experimental mouse models in which a small piece of human tumour is implanted in the same organ of origin.
Anna Portela, PhD, CEO
About Akademiska Sjukhuset, PET Centre
Akademiska Sjukhuset is a leading University hospital in Sweden with 8000 employees. The PET Centre at the hospital was created in 1991 and performs about 1900 clinical PET investigations per year including around 350 for clinical research, with 25 different PET tracers. PET Centre also performs research in radiochemistry and preclinical PET.
Gunnar Antoni, PhD, Adj Prof. Head of PET Centre